Ranolazine is associated with cardiovascular and metabolic improvement: a win-win for patients with diabetes

Eur Heart J. 2006 Jan;27(1):5-6. doi: 10.1093/eurheartj/ehi624. Epub 2005 Nov 2.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Acetanilides
  • Angina Pectoris / drug therapy*
  • Angina Pectoris / physiopathology
  • Cardiotonic Agents / therapeutic use*
  • Diabetic Angiopathies / drug therapy*
  • Diabetic Angiopathies / physiopathology
  • Exercise Tolerance
  • Humans
  • Piperazines / therapeutic use*
  • Ranolazine

Substances

  • Acetanilides
  • Cardiotonic Agents
  • Piperazines
  • Ranolazine